These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 20353536

  • 1. Role of targeted therapy in the treatment of advanced prostate cancer.
    Fizazi K, Sternberg CN, Fitzpatrick JM, Watson RW, Tabesh M.
    BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536
    [Abstract] [Full Text] [Related]

  • 2. New drugs in prostate cancer.
    Armstrong AJ, Carducci MA.
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [Abstract] [Full Text] [Related]

  • 3. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H, Garcia JA.
    Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
    [Abstract] [Full Text] [Related]

  • 4. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
    Armstrong AJ, Febbo PG.
    Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
    [Abstract] [Full Text] [Related]

  • 5. Targeted therapy for advanced prostate cancer: Looking through new lenses.
    Vogiatzi P, Cassone M, Claudio L, Claudio PP.
    Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
    [Abstract] [Full Text] [Related]

  • 6. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW.
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [Abstract] [Full Text] [Related]

  • 7. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS.
    J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
    [Abstract] [Full Text] [Related]

  • 8. Update on castrate-resistant prostate cancer: 2010.
    Lassi K, Dawson NA.
    Curr Opin Oncol; 2010 May; 22(3):263-7. PubMed ID: 20177381
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic approach to hormone-refractory prostate cancer.
    Saad F, Al Dejmah A, Perrotte P, McCormack M, Bénard F, Valiquette L, Karakiewicz PI.
    Can J Urol; 2006 Apr; 13 Suppl 2():52-6. PubMed ID: 16672130
    [Abstract] [Full Text] [Related]

  • 10. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
    Tenta R, Sotiriou E, Pitulis N, Thyphronitis G, Koutsilieris M.
    J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
    [Abstract] [Full Text] [Related]

  • 11. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 12. Treatment options in androgen-independent prostate cancer.
    Lara PN, Meyers FJ.
    Cancer Invest; 1999 Jan; 17(2):137-44. PubMed ID: 10071598
    [Abstract] [Full Text] [Related]

  • 13. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D, Tiserová H, Fucíková J, Last'ovicka J, Podrazil M, Ulcová H, Budínský V, Prausová J, Linke Z, Minárik I, Sedivá A, Spísek R, Bartůnková J.
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [Abstract] [Full Text] [Related]

  • 14. Management of high risk metastatic prostate cancer: the case for novel therapies.
    Brand TC, Tolcher AW.
    J Urol; 2006 Dec; 176(6 Pt 2):S76-80; discussion S81-2. PubMed ID: 17084174
    [Abstract] [Full Text] [Related]

  • 15. The role of systemic cytotoxic therapy for prostate cancer.
    Chang SS, Kibel AS.
    BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524
    [Abstract] [Full Text] [Related]

  • 16. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS.
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [Abstract] [Full Text] [Related]

  • 17. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 18. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG, Crawford ED, DeAntoni EP.
    Eur Urol; 1997 Sep; 32 Suppl 3():70-7. PubMed ID: 9267789
    [Abstract] [Full Text] [Related]

  • 19. New molecular targets in advanced prostate cancer.
    Dawson NA.
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
    [Abstract] [Full Text] [Related]

  • 20. Novel targets and approaches in advanced prostate cancer.
    Hadaschik BA, Sowery RD, Gleave ME.
    Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.